<unk>  <unk>  belongs to the lipoprotein particle family.  There is a direct association between high<unk>  and cardiovascular disease.  Environmental and genetic factors are involved in the pathophysiology of high<unk> .  Several conditions may contribute to the pathophysiology of high<unk> , such as diet high in saturated fat, hypothyroidism, nephrotic syndrome, pregnancy, obesity, or medications such as amiodarone, cyclosporine, diuretics, and glucocorticoids.  Prior approaches to the management of<unk>  aimed towards the classification of<unk>  concentrations and the treatment of subjects with dyslipidemia to a target<unk>  concentration.  In 2001, the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III classified<unk>  concentrations into optimal, near optimal, borderline high, high, and very high.  However, the latest 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults no longer takes into consideration<unk>  cut-off concentration but rather identifies groups of patients among whom the benefit of statin outweighs the risk of adverse events.  There is an unmet need for more effective and tolerable therapies for the reduction of<unk> -c, which is driving ongoing and future investigational therapies.
Low density lipoprotein
High density lipoprotein
Apolipoprotein
Diglyceride
Lipoprotein
Cholesterol
Braun's lipoprotein
Lipase